Hoth Therapeutics
HOTHHOTH · Stock Price
Historical price data
Overview
Hoth Therapeutics is a US-based, publicly traded biopharmaceutical company (NASDAQ: HOTH) dedicated to developing innovative, targeted therapeutics for conditions with high unmet need, particularly in dermatology and chronic wound care. Its primary asset is the proprietary BioLexa Platform, a topical treatment in development for atopic dermatitis (eczema). The company's strategy involves leveraging this platform technology to expand its pipeline across oncology, neurology, and inflammatory dermatology while operating as a pre-revenue, clinical-stage entity subject to the volatility of the micro-cap biotech sector.
Technology Platform
The BioLexa Platform is a proprietary topical treatment technology, positioned as a unique targeted therapeutic for dermatological and chronic wound disorders, with its initial application in atopic dermatitis.
Pipeline
2| Drug | Indication | Stage | Watch |
|---|---|---|---|
| HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% ... | Acneiform Eruption Due to Chemical | Phase 2 | |
| BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + Gentamicin | Atopic Dermatitis | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Hoth faces intense competition in dermatology from large pharma with marketed products and numerous biotechs. Its competitive edge relies solely on demonstrating clinical superiority or differentiation with its unproven BioLexa Platform in a crowded field.